Prescribing information

 

____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Explore our range of useful resources designed to support you and your SPMS patients.

You can access materials and educational webinars that will provide you with more in-depth information about MAYZENT, and support you in the day-to-day management of patients receiving MAYZENT. You can download some of the patient materials to share with your patients.

If you would like to receive printed copies of any of these materials, please contact your local MAYZENT key account manager.

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference:

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | June 2021 | 103440
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]